WACKER at a Glance

As an innovative chemical company, WACKER makes a vital contribution to improving the quality of life around the world. We want to continue developing and supplying solutions that meet our own expectations – namely to add value for our customers and shareholders, and to achieve sustainable growth.

 (XLS:) Download XLS

 

  

 

  

 

€ million

  

2019

  

2018

  

Change in %

1

EBITDA is EBIT before depreciation/amortization and impairments.

2

Margins are calculated based on sales.

3

EBIT is the result from continuing operations for the period before interest result and other financial result, and income taxes. In 2019, depreciation/amortization and impairments reflected the impairment charge of € 760 million on the fixed assets of WACKER POLYSILICON.

4

Sum of cash and cash equivalents, noncurrent and current securities, and noncurrent and current financial liabilities.

5

Intangible assets, property, plant and equipment, investment property, excluding right-of-use assets.

6

Sum of cash flow from operating activities and cash flow from long-term investing activities (before securities).

 

  

 

  

 

  

 

Results/Return

  

 

  

 

  

 

Sales

  

4,927.6

  

4,978.8

  

-1.0

EBITDA1

  

783.4

  

930.0

  

-15.8

EBITDA margin2 (%)

  

15.9

  

18.7

  

n.a.

EBIT3

  

-536.3

  

389.6

  

n.a.

EBIT margin2 (%)

  

-10.9

  

7.8

  

n.a.

 

  

 

  

 

  

 

Financial result

  

-54.9

  

-65.2

  

-15.8

Income before income taxes

  

-591.2

  

324.4

  

n.a.

Net result for the year

  

-629.6

  

260.1

  

n.a.

 

  

 

  

 

  

 

Earnings per share (basic/diluted) (€)

  

-12.94

  

4.95

  

n.a.

ROCE (%)

  

-11.3

  

5.9

  

n.a.

 

  

 

  

 

  

 

Financial Position/Cash Flows

  

 

  

 

  

 

Total assets

  

6,491.0

  

7,118.7

  

-8.8

Equity

  

2,029.0

  

3,145.5

  

-35.5

Equity ratio (%)

  

31.3

  

44.2

  

n.a.

Financial liabilities

  

1,258.9

  

997.2

  

26.2

Net financial debt4

  

713.7

  

609.7

  

17.1

Capital expenditures5

  

379.5

  

460.9

  

-17.7

Depreciation/amortization and impairments

  

-1,319.7

  

-540.4

  

>100

Net cash flow6

  

184.4

  

86.2

  

>100

 

  

 

  

 

  

 

Research and Development

  

 

  

 

  

 

Research and development expenses

  

173.3

  

164.6

  

5.3

 

  

 

  

 

  

 

Employees

  

 

  

 

  

 

Personnel expenses

  

1,253.8

  

1,231.5

  

1.8

Employees (December 31, number)

  

14,658

  

14,542

  

0.8

todo Vorjahresvergleich